Last reviewed · How we verify

NCT03554733

Bridge Reinvention

Completed NA Last updated 13 June 2018
What this trial tests

NA trial testing ReInventing Yourself after SCI in Spinal Cord Injuries in 46 participants. Completed in 30 April 2018.

Timeline
1 April 2014
Primary endpoint
30 April 2018
30 April 2018

Quick facts

Lead sponsorCraig Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment46
Start date1 April 2014
Primary completion30 April 2018
Estimated completion30 April 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Craig Hospital

Who can join

18 and older, any sex, with Spinal Cord Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomized controlled trial is to determine the efficacy of a treatment to improve resilience to stress for individuals with SCI who are transitioning from inpatient rehabilitation to home. The overarching hypothesis is that individuals who participate in an intervention that presents positive psychotherapy topics in an interactive, structured, cognitive-behaviorally-based group intervention that stresses restructuring maladaptive thought processes and provides experiential opportunities to reinforce behavioral change will demonstrate increased self-efficacy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

Other Craig Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03554733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing